3 HMO Stocks in Focus Despite Rising Medical Costs, Regulatory Pressures

Zacks says the Medical-HMO industry faces margin pressure from rising medical and drug costs, regulatory uncertainty around Medicaid/Medicare and ACA policy, and workforce shortages, prompting insurers to prioritize commercial books and consider M&A—which could accelerate if expected Fed rate cuts in 2025–26 lower financing costs. The industry is rated poorly by Zacks (Industry Rank #212, bottom 12%), has underperformed the market (down 25.8% over the past year versus the S&P 500’s +2.4%), and trades at a modest forward P/E of 16.04x versus the S&P’s 23.35x and the broader sector’s 20.92x. Zacks highlights UnitedHealth, Humana and Centene as Hold candidates—citing UNH’s diversified UnitedHealthcare/Optum mix with a $16.29 2025 EPS consensus and 11.9% revenue growth, HUM’s $17.08 EPS consensus and ~10% revenue growth, and CNC’s $2.00 EPS consensus with an 18.5% revenue growth projection—positions it views as worth retaining despite the bleak near-term industry outlook.

Analysis

The Zacks piece identifies material near-term headwinds for the Medical‑HMO industry driven by rising medical and drug costs, higher utilization of previously deferred care, and demographic trends that are compressing Health Benefit Ratios and margins. Zacks places the industry at Industry Rank #212 (bottom 12%), and notes a 25.8% decline over the past year versus the S&P 500’s +2.4% and the broader medical sector’s +14.3%, signaling negative aggregate earnings revisions and weak market sentiment.

On valuation and capital activity, the industry trades at a forward 12‑month P/E of 16.04x versus the S&P 500 at 23.35x and the sector at 20.92x, near its five‑year median (16.2x), implying cheaper multiples but also reflecting earnings risk. Zacks highlights that anticipated Fed rate cuts in 2025–26 could lower borrowing costs and encourage M&A, which insurers are pursuing to diversify, grow commercial book share and offset low‑margin public programs.

Zacks spotlights UnitedHealth (UNH: 2025 EPS consensus $16.29, revenues +11.9% y/y), Humana (HUM: 2025 EPS $17.08, revenues +10% y/y) and Centene (CNC: 2025 EPS $2.00, revenues +18.5% y/y) as Hold/retain candidates, noting mixed recent beat/miss patterns. Major downside catalysts remain regulatory changes (proposals affecting Medicaid/Medicare/ACA) and workforce shortages that can impair provider capacity, while a projected Medicare Advantage rate bump in 2026 could provide partial margin relief.

Key Decisions for Investors

• Underweight the Medical‑HMO group relative to the S&P given the industry’s -25.8% one‑year performance and Zacks Industry Rank #212,
• If already long, retain selective positions in UNH, HUM and CNC rather than adding aggressively—their consensus 2025 EPS/revenue growth (UNH $16.29; HUM $17.08; CNC $2.00) supports holding but not enlargement,
• Monitor regulatory developments (Medicaid/Medicare/ACA proposals) and claims/utilization trends closely and be prepared to hedge or reduce exposure if policy changes lower reimbursement or claims inflation persists,
• Watch for M&A and event‑driven entry points ahead of or following Fed rate cuts in 2025–26 and consider selectively buying on confirmed improvement in claims trends given the industry’s cheaper forward P/E (16.04x) versus the market